Aeovian Pharmaceuticals
PrivateLast Round
Series B
Dec 16, 2025
Total Funding Raised
$142M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Aeovian Pharmaceuticals operates in Healthcare & Life Sciences and is based in Berkeley, California. Its latest recorded funding round was a Series B round in December 2025.
Aeovian Pharmaceuticals is a biotechnology company that develops targeted and highly selective small molecule therapeutics to restore cellular metabolic quality control for the treatment of rare and age-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aeovian Pharmaceuticals Comparables
Compare Aeovian Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cambrian Bio | 82% | |
| Aukera Therapeutics | 77% | |
| Novartis | 74% |
For institutional investors. Book with your work email.
Aeovian Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 16, 2025 | ||||
| Series A Extension | Mar 28, 2024 | ||||
| Series A | Oct 3, 2019 | ||||
| Seed | Dec 11, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Aeovian Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Apollo Ventures | Seed |
| SymBiosis Capital Management | Series B |
| CTI Life Sciences Fund | Series B |
| TSC Alliance Endowment Fund | Series B |
| Hevolution Foundation | Series B, Series A Extension |
| LUMA Partners | Series B |
| Foresite Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 49% MoM, reaching 2.6K.
- Jun 20, 2026
Monthly visitors increased 133% MoM, reaching 1.6K.
For institutional investors. Book with your work email.
Aeovian Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aeovian Pharmaceuticals's valuation, stock price, and market status.
Is Aeovian Pharmaceuticals a public or private company?
Aeovian Pharmaceuticals is a private company.
What is the current stock price of Aeovian Pharmaceuticals?
Aeovian Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Aeovian Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aeovian Pharmaceuticals worth (valuation)?
Valuation information for Aeovian Pharmaceuticals is not publicly available.
Can I buy Aeovian Pharmaceuticals stock?
Aeovian Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aeovian Pharmaceuticals's last funding round?
Aeovian Pharmaceuticals's most recent funding round was Series B on December 16, 2025.
Who are the main investors in Aeovian Pharmaceuticals?
Key investors in Aeovian Pharmaceuticals include Apollo Ventures, CTI Life Sciences Fund, Hevolution Foundation, LUMA Partners, venBio.
Will Aeovian Pharmaceuticals IPO soon?
No public IPO plans have been announced for Aeovian Pharmaceuticals.
How can I track Aeovian Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Aeovian Pharmaceuticals's shares on secondary markets.